ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Coronavirus trials for Actemra arthritis drug to start in Japan

Chugai and Roche's medication already set for tests in US

The trials will determine whether the arthritis treatment is effective against pneumonia caused by coronavirus infection.   © Reuters

TOKYO -- Chugai Pharmaceutical will conduct a clinical trial in Japan using its Actemra arthritis medication to treat patients with coronavirus-induced pneumonia.

The study's time frame and other details need to be finalized, the Tokyo-based company said Wednesday. Its Swiss parent, Roche Group, said last month that it was launching similar clinical trials in other countries including the U.S., where the Food and Drug Administration last month fast tracked the drug as a coronavirus treatment.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more